Skip to main content

Table 1 Patients' characteristics

From: Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

Characteristic No. Median (range)
Age at salvage RT (years)   67 (49-81)
Pathologic tumor stage   
T1 2  
T2 41  
T3 57  
T4 1  
Unknown 2  
Surgical margin   
Positive 48  
Negative 51  
Unknown 3  
Gleason score   
≤ 6 31  
7 35  
8 ≥ 31  
Unknown 5  
Preoperative PSA (ng/ml)   8.8 (1.6-120)
< 10 58  
≥ 10 44  
Pre-RT PSA (ng/ml)   0.240 (0.011-0.994)
< 0.25 52  
≥ 0.25 50  
PSA doubling time (months)   6.83 (0.58-41.9)
< 7 43  
≥ 7 43  
Not available 16  
RT dose (Gy) (BED, α/β = 1.5)   64 (149.3) (60-72 [129.6-163.3])
60 at 2 daily (140.0) 18  
62 at 2 daily (144.7) 1  
64 at 2 daily (149.3) 67  
64.8 at 1.8 daily (142.6) 12  
70 at 2 daily (163.3) 3  
72 at 1.2 per fraction twice daily (HF) (129.6) 1  
Time from RP to RT (months)   21 (5-99)
< 24 56  
≥ 24 46  
Hormone therapy   
Done 29  
Not done 73  
  1. Abbreviations: RT = radiotherapy, PSA = prostate-specific antigen, BED = biological effective dose, HF = hyperfractionation, RP = radical prostatectomy